Safe Use of Glimepiride in Older Women with Type 2 Diabetes

Primary Safety Concerns

• Sulfonylureas, including glimepiride, are identified as hypoglycemia-causing medications that should be deintensified or switched to lower-risk alternatives in older adults at high risk for hypoglycemia, according to the American Diabetes Association 1, 2, 3
• The 2025 American Diabetes Association guidelines recommend selecting medications with low risk of hypoglycemia in older adults, particularly those with hypoglycemia risk factors 1, 2

Clinical Scenarios Favoring Use

• Cost is a major barrier, and newer agents (GLP-1 agonists, SGLT2 inhibitors, DPP-4 inhibitors) are unaffordable, making glimepiride a consideration 1, 3
• Patient is "healthy" (few coexisting chronic illnesses) with good cognitive and functional status, and glimepiride may be appropriate 1, 2

Practical Prescribing Algorithm

• Assess cognitive function, activities of daily living (ADL) impairment, current eGFR, history of hypoglycemia or hypoglycemia unawareness, polypharmacy burden, and living situation and social support availability before prescribing glimepiride 1, 2, 4
• Start glimepiride at 0.5-1 mg once daily, with slow titration and close monitoring, as recommended by the American Diabetes Association 6

Strongly Preferred Alternatives

• The American Diabetes Association explicitly prioritizes metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors over sulfonylureas in older adults due to their lower hypoglycemia risk 1, 2, 3, 5, 7

When to Deintensify or Discontinue Glimepiride

• Immediately reassess and likely discontinue glimepiride if any severe hypoglycemic episode occurs, or if there is recurrent mild-moderate hypoglycemia, development of new cognitive impairment or ADL decline, hospitalization or acute illness, or A1C consistently <7.0% 1, 2, 3, 4, 7